Table 2.

 Characteristics of patients

Characteristics	Aprepitant 125/80 mg + standard therapy (n = 146)	Aprepitant 40/25 mg + standard therapy (n = 143)	Standard therapy (n = 150)
Sex (%)
Female	24.0	25.2	25.3
Male	76.0	74.8	74.7
Age (%)
≥65 years	37.0	51.7	42.0
<65 years	63.0	48.3	58.0
Mean (SD)	60.5 (9.7)	63.3 (9.4)	62.2 (9.8)
Use of concurrent emetogenic chemotherapy† (% of patients)	17.8	15.4	20.0
Cisplatin dose (% of patients)
<70	0.0	0.0	0.0
≥70, <80	41.8	42.0	46.7
≥80, <90	56.2	57.3	52.7
≥90, <100	0.0	0.0	0.0
≥100	2.1	0.7	0.7
Mean dose (mg/m2)	76.9	76.9	76.2
Alcoholic drinks/week (at the time of informed consent) (% of patients)
None	57.5	61.5	58.0
Several times per month	10.3	6.3	10.7
3–4 times per week	6.2	3.5	7.3
Almost every day	26.0	28.7	24.0
History of morning sickness (% of patients)	43.3	38.2	44.1
History of motion sickness (% of patients)	9.6	4.2	11.3
History of cisplatin chemotherapy (% of patients)	17.8	15.4	17.3
History of chemotherapy except cisplatin (% of patients)	19.9	24.5	18.7
History of CINV except cisplatin chemotherapy (% of patients)	41.4	37.1	42.9
Primary cancer diagnosis (% of patients)‡	(n = 150)	(n = 148)	(n = 151)
Respiratory	73.3	73.0	70.2
Urogenital	16.7	13.5	14.6
Digestive	4.0	5.4	4.6
Eyes/ears/nose/throat	3.3	4.7	7.3
Other	3.3	3.4	3.3

†Hesketh level ≥3; analysis population: full analysis set. ‡Analysis population: safety analysis set. SD, standard deviation.